This inventor holds 1 USPTO granted patent. Top assignee: Abelzeta Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Jiaping He: Innovator in Chimeric Antigen Receptor Technology
Introduction
Jiaping He is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of immunotherapy, particularly in the development of chimeric antigen receptors (CARs). His work focuses on enhancing the efficacy of engineered T cells for targeted cancer therapies.
Latest Patents
Jiaping He holds a patent titled "Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof." This patent represents a crucial advancement in the treatment of cancers that express the CD20 antigen, such as certain types of lymphoma and leukemia. He has 1 patent to his name, showcasing his innovative approach to cancer treatment.
Career Highlights
He is currently employed at Abelzeta Inc., where he continues to push the boundaries of cancer research and therapy. His work at the company emphasizes the importance of targeted therapies in improving patient outcomes.
Collaborations
Jiaping He collaborates with talented individuals in his field, including Yihong Yao and Jiaqi Huang. These partnerships enhance the research and development efforts at Abelzeta Inc., fostering innovation and progress in cancer treatment.
Conclusion
Jiaping He is a pioneering inventor whose work in chimeric antigen receptor technology is making a significant impact in the field of cancer therapy. His contributions are paving the way for more effective treatments and improved patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile